Does BLINATUMOMAB Cause Second primary malignancy? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Second primary malignancy have been filed in association with BLINATUMOMAB (BLINCYTO). This represents 0.1% of all adverse event reports for BLINATUMOMAB.
9
Reports of Second primary malignancy with BLINATUMOMAB
0.1%
of all BLINATUMOMAB reports
4
Deaths
3
Hospitalizations
How Dangerous Is Second primary malignancy From BLINATUMOMAB?
Of the 9 reports, 4 (44.4%) resulted in death, 3 (33.3%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BLINATUMOMAB. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does BLINATUMOMAB Cause?
Pyrexia (1,064)
Acute lymphocytic leukaemia recurrent (977)
Cytokine release syndrome (952)
Off label use (590)
Death (588)
Neurotoxicity (530)
Drug ineffective (345)
Headache (335)
Neutropenia (265)
Febrile neutropenia (262)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BLINATUMOMAB Alternatives Have Lower Second primary malignancy Risk?
BLINATUMOMAB vs BLONANSERIN
BLINATUMOMAB vs --BLOOD-COAGULATION FACTOR VIII FUSION PROTEIN WITH IMMUNOGLOBULIN G1 , ,-BIS WITH IMMUNOGLOBULIN G1
BLINATUMOMAB vs BOCEPREVIR
BLINATUMOMAB vs BOCOCIZUMAB
BLINATUMOMAB vs BONIVA